Shares of Tvardi Therapeutics shifted sharply higher Thursday, rising 9.4% to $1.16, after the company published preclinical data showing its oral drug candidate concentrated in colon tissue and prevented tumor formation in a mouse model of chronic colitis. The study, published in the International Journal of Molecular Sciences, tested Tvardi's first-generation oral drug in a mouse model designed to replicate the human progression from chronic colitis to colorectal cancer. The drug reached effective concentrations in the colon, normalized disease-linked gene activity, and prevented the development of colon polyps and adenocarcinomas. The bounce arrived mid-selloff: the stock had fallen roughly 29% over the prior five sessions.

  • The Drug Got to the Right Place — That Matters for the Next Step. The oral compound accumulated in the colon at approximately 8-fold higher concentrations than in the bloodstream , a key detail because ulcerative colitis drugs need to reach the gut, not circulate widely. This is now the fourth preclinical colitis model showing biological activity for Tvardi's compounds. But this data supports the older drug; the company's next-generation version is the one it plans to bring into patient trials. More than 70% of UC patients do not achieve remission with currently approved therapies , a gap Tvardi hopes to fill — inside a UC treatment market projected at roughly $11.5 billion in 2026.

  • The Cash Clock Is the Real Story. Tvardi held $15.8 million in cash as of June 30, 2026, down from $30.8 million at year-end 2025. At the Q1 burn rate of roughly $6.5–$6.8 million per quarter, the company itself has said its runway extends only into Q4 2026.

Launching its next-generation drug into a UC clinical trial depends on regulatory clearance and additional funding — meaning a capital raise is likely imminent, which could dilute current shareholders. The market cap sits at roughly $16.6 million , leaving little room for negotiating leverage.

  • Preclinical Is Still a Long Way From Revenue. Tvardi generates no product revenue. Mouse results, while encouraging, fail the vast majority of the time when tested in humans. One analyst maintains a $9 price target — nearly eight times the current price — but earnings-based valuations are not applicable due to ongoing losses, and third-party financial scores remain extremely low.

  • What to Watch Next. Topline results from the Phase 2 liver-cancer trial are expected in the second half of 2026. That readout, plus any financing announcement, will matter far more than today's mouse study for determining whether Tvardi's science — and stock — can survive into 2027.